Mendelian randomization in cardiometabolic disease: Challenges in evaluating causality

Nature Reviews Cardiology

Volumn 14, Issue 10, 2017, Pages 577-599

  Holmes, Michael V ^a,b,c,d   Ala Korpela, Mika ^d,e   Smith, George Davey ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; C REACTIVE PROTEIN; EXTRACELLULAR SUPEROXIDE DISMUTASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ALCOHOL CONSUMPTION; ALDH2 GENE; APOE GENE; CRP GENE; DIABETES MELLITUS; ECSOD GENE; ESOPHAGUS CARCINOMA; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE SEQUENCE; GENETIC RISK; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMAN; HYPERTENSION; IL6R GENE; ISCHEMIC HEART DISEASE; LIMIT OF QUANTITATION; MENDELIAN RANDOMIZATION ANALYSIS; PHENOTYPE; PPM1K GENE; PRIORITY JOURNAL; RELIABILITY; REVIEW; SCARB1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CORONARY ARTERY DISEASE; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; MULTIFACTORIAL INHERITANCE; PROCEDURES; RISK FACTOR;

BIOMARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MENDELIAN RANDOMIZATION ANALYSIS; MULTIFACTORIAL INHERITANCE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 85027694919     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2017.78     Document Type: Review

References (152)

1. Fewell, Z., Davey Smith, G. & Sterne, J. A. The impact of residual and unmeasured confounding in epidemiologic studies: A simulation study. Am. J. Epidemiol. 166, 646-655 (2007).
2. Davey Smith, G. et al. Clustered environments and randomized genes: A fundamental distinction between conventional and genetic epidemiology. PLoS Med. 4, e352 (2007).
3. Harrison, R. K. Phase II and phase III failures: 2013-2015. Nat. Rev. Drug Discov. 15, 817-818 (2016).
4. Fordyce, C. B. et al. Cardiovascular drug development: is it dead or just hibernating J. Am. Coll. Cardiol. 65, 1567-1582 (2015).
5. Wang, Q. et al. Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence. Int. J. Epidemiol. 45, 1445-1457 (2016).
6. Corrao, G., Rubbiati, L., Bagnardi, V., Zambon, A. & Poikolainen, K. Alcohol and coronary heart disease: A meta-analysis. Addiction 95, 1505-1523 (2000).
7. Marmot, M. & Brunner, E. Alcohol and cardiovascular disease: The status of the U shaped curve. BMJ 303, 565-568 (1991).
8. Kloner, R. A. & Rezkalla, S. H. To drink or not to drink That is the question. Circulation 116, 1306-1317 (2007).
9. Mukamal, K. J. & Rimm, E. B. Alcohol's effects on the risk for coronary heart disease. Alcohol Res. Health 25, 255-261 (2001).
10. Davey Smith, G. & Hemani, G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum. Mol. Genet. 23, R89-R98 (2014).
11. Davey Smith, G. & Ebrahim, S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease Int. J. Epidemiol. 32, 1-22 (2003).
12. Swerdlow, D. I. et al. Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. Int. J. Epidemiol. 45, 1600-1616 (2016).
13. Evans, D. M. & Davey Smith, G. Mendelian randomization: new applications in the coming age of hypothesis-free causality. Annu. Rev. Genomics Hum. Genet. 16, 327-350 (2015).
14. Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856-860 (2015).
15. Ference, B. A. et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: A Mendelian randomization analysis. J. Am. Coll. Cardiol. 60, 2631-2639 (2012).
16. Holmes, M. V. et al. Mendelian randomization of blood lipids for coronary heart disease. Eur. Heart J. 36, 539-550 (2015).
17. Voight, B. F. et al. Plasma HDL cholesterol and risk of myocardial infarction: A Mendelian randomisation study. Lancet 380, 572-580 (2012).
18. White, J. et al. Association of lipid fractions with risks for coronary artery disease and diabetes. JAMA Cardiol. 1, 692-699 (2016).
19. Cholesterol Treatment Trialists' Collaborators et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670-1681 (2010).
20. Collins, R. et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388, 2532-2561 (2016).
21. Silverman, M. G. et al. Association between lowering LDLC and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. JAMA 316, 1289-1297 (2016).
22. C Reactive Protein Coronary Heart Disease Genetics Collaboration et al. Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. BMJ 342, d548 (2011).
23. Zacho, J. et al. Genetically elevated Creactive protein and ischemic vascular disease. N. Engl. J. Med. 359, 1897-1908 (2008).
24. Holmes, M. V. et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ 349, g4164 (2014).
25. Hagg, S. et al. Adiposity as a cause of cardiovascular disease: A Mendelian randomization study. Int. J. Epidemiol. 44, 578-586 (2015).
26. Nordestgaard, B. G. et al. The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach. PLoS Med. 9, e1001212 (2012).
27. Emdin, C. A. et al. Genetic association of waisttohip ratio with cardiometabolic traits, type 2 diabetes, and coronary heart disease. JAMA 317, 626-634 (2017).
28. Dale, C. et al. Causal associations of adiposity and body fat distribution with coronary heart disease, stroke subtypes and type 2 diabetes: A Mendelian randomization analysis. Circulation http://dx.doi.org/ 10.1161/CIRCULATIONAHA.116.026560
29. Look AHEAD Research Group et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N. Engl. J. Med. 369, 145-154 (2013).
30. Wurtz, P. et al. Metabolomic profiling of statin use and genetic inhibition of HMG-CoA reductase. J. Am. Coll. Cardiol. 67, 1200-1210 (2016).
31. Swerdlow, D. I. et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 385, 351-361 (2014).
32. Holmes, M. V. et al. Secretory phospholipase A2-IIA and cardiovascular disease: A Mendelian randomization study. J. Am. Coll. Cardiol. 62, 1966-1976 (2013).
33. Nicholls, S. J. et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: The VISTA16 randomized clinical trial. JAMA 311, 252-262 (2014).
34. Polfus, L. M., Gibbs, R. A. & Boerwinkle, E. Coronary heart disease and genetic variants with low phospholipase A2 activity. N. Engl. J. Med. 372, 295-296 (2015).
35. STABILITY Investigators et al. Darapladib for preventing ischemic events in stable coronary heart disease. N. Engl. J. Med. 370, 1702-1711 (2014).
36. Millwood, I. Y. et al. Lipoprotein-associated phospholipase A2 lossoffunction variant and risk of vascular diseases in 90,000 Chinese adults. J. Am. Coll. Cardiol. 67, 230-231 (2016).
37. Millwood, I. Y. et al. A phenome-wide association study of a lipoprotein-associated phospholipase A2 lossoffunction variant in 90 000 Chinese adults. Int. J. Epidemiol. 45, 1588-1599 (2016).
38. Talmud, P. J. & Holmes, M. V. Deciphering the causal role of sPLA2s and LpPLA2 in coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 35, 2281-2289 (2015).
39. Ference, B. A., Majeed, F., Penumetcha, R., Flack, J. M. & Brook, R. D. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: A 2 × 2 factorial Mendelian randomization study. J. Am. Coll. Cardiol. 65, 1552-1561 (2015).
40. Schmidt, A. F. et al. PCSK9 genetic variants and risk of type 2 diabetes: A Mendelian randomisation study. Lancet Diabetes Endocrinol. 5, 97-105 (2017).
41. Ference, B. A. et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N. Engl. J. Med. 375, 2144-2153 (2016).
42. Lotta, L. A. et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: A meta-analysis. JAMA 316, 1383-1391 (2016).
43. Guasch-Ferre, M. et al. Metabolomics in prediabetes and diabetes: A systematic review and meta-analysis. Diabetes Care 39, 833-846 (2016).
44. Soininen, P., Kangas, A. J., Wurtz, P., Suna, T. & AlaKorpela, M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ. Cardiovasc. Genet. 8, 192-206 (2015).
45. Wurtz, P. et al. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care 36, 648-655 (2013).
46. Wurtz, P. et al. Circulating metabolite predictors of glycemia in middle-aged men and women. Diabetes Care 35, 1749-1756 (2012).
47. Wurtz, P. et al. Metabolic signatures of insulin resistance in 7,098 young adults. Diabetes 61, 1372-1380 (2012).
48. Wang, T. J. et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 17, 448-453 (2011).
49. Lotta, L. A. et al. Genetic predisposition to an impaired metabolism of the branched-chain amino acids and risk of type 2 diabetes: A Mendelian randomisation analysis. PLoS Med. 13, e1002179 (2016).
50. Elliott, P. et al. Genetic loci associated with Creactive protein levels and risk of coronary heart disease. JAMA 302, 37-48 (2009).
51. Evans, D. M. et al. Mining the human phenome using allelic scores that index biological intermediates. PLoS Genet. 9, e1003919 (2013).
52. Prins, B. P. et al. Investigating the causal relationship of Creactive protein with 32 complex somatic and psychiatric outcomes: A large-scale cross-consortium Mendelian randomization study. PLoS Med. 13, e1001976 (2016).
53. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int. J. Epidemiol. 44, 512-525 (2015).
54. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet. Epidemiol. 40, 304-314 (2016).
55. Zanoni, P. et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science 351, 1166-1171 (2016).
56. Ledford, H. 'Good' cholesterol mutation linked to heart disease. Nature http://www.nature.com/news/ good-cholesterol-mutation-linked-to-heart-disease-1.19543WT.mc-id=FBK-NA-1603-NEWSCHOLESTEROLMUTATION-PORTFOLIO (2016).
57. Harb, J. Why having too much 'good' cholesterol can actually be BAD for you. Daily Mail http://www. dailymail.co.uk/health/article-3384473/Why-having-good-cholesterol-actually-BAD-you.html (2016).
58. Tall, A. R. An overview of reverse cholesterol transport. Eur. Heart J. 19 (Suppl. A), A31-A35 (1998).
59. Rosenson, R. S. et al. Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. Circulation 125, 1905-1919 (2012).
60. Zhang, Y. et al. Hepatic expression of scavenger receptor class B type I (SRBI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J. Clin. Invest. 115, 2870-2874 (2005).
61. Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122 (2007).
62. Schwartz, G. G. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089-2099 (2012).
63. Eli Lilly and Company. Lilly to discontinue development of evacetrapib for high-risk atherosclerotic cardiovascular disease. Lilly https://investor.lilly.com/ releasedetail.cfmReleaseID=936130 (2015).
64. Rohatgi, A. et al. HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 371, 2383-2393 (2014).
65. Anastasius, M. et al. Cholesterol efflux capacity: An introduction for clinicians. Am. Heart J. 180, 54-63 (2016).
66. Rosenson, R. S. et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat. Rev. Cardiol. 13, 48-60 (2016).
67. Kingwell, B. A., Chapman, M. J., Kontush, A. & Miller, N. E. HDL-targeted therapies: progress, failures and future. Nat. Rev. Drug Discov. 13, 445-464 (2014).
68. Hunter, C. A. & Jones, S. A. IL6 as a keystone cytokine in health and disease. Nat. Immunol. 16, 448-457 (2015).
69. Lissilaa, R. et al. Although IL6 trans-signaling is sufficient to drive local immune responses, classical IL6 signaling is obligate for the induction of T cell-mediated autoimmunity. J. Immunol. 185, 5512-5521 (2010).
70. IL6R Genetics Consortium Emerging Risk Factors Collaboration et al. Interleukin6 receptor pathways in coronary heart disease: A collaborative meta-analysis of 82 studies. Lancet 379, 1205-1213 (2012).
71. Interleukin6 Receptor Mendelian Randomisation Analysis Consortium. The interleukin6 receptor as a target for prevention of coronary heart disease: A Mendelian randomisation analysis. Lancet 379, 1214-1224 (2012).
72. Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685-1695 (2005).
73. Rafiq, S. et al. A common variant of the interleukin 6 receptor (IL6r) gene increases IL6r and IL6 levels, without other inflammatory effects. Genes Immun. 8, 552-559 (2007).
74. Mullberg, J. et al. The soluble human IL6 receptor. Mutational characterization of the proteolytic cleavage site. J. Immunol. 152, 4958-4968 (1994).
75. Rose-John, S. IL6 trans-signaling via the soluble IL6 receptor: importance for the pro-inflammatory activities of IL6. Int. J. Biol. Sci. 8, 1237-1247 (2012).
76. Kleveland, O. et al. Effect of a single dose of the interleukin6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with nonSTelevation myocardial infarction: A double-blind, randomized, placebo-controlled phase 2 trial. Eur. Heart J. 37, 2406-2413 (2016).
77. Richmond, R. C., Hemani, G., Tilling, K., Davey Smith, G. & Relton, C. L. Challenges and novel approaches for investigating molecular mediation. Hum. Mol. Genet. 25, R149-R156 (2016).
78. Secretan, B. et al. A review of human carcinogens-part E: Tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 10, 1033-1034 (2009).
79. Cho, Y. et al. Alcohol intake and cardiovascular risk factors: A Mendelian randomisation study. Sci. Rep. 5, 18422 (2015).
80. Brooks, P. J., Enoch, M. A., Goldman, D., Li, T. K. & Yokoyama, A. The alcohol flushing response: An unrecognized risk factor for esophageal cancer from alcohol consumption. PLoS Med. 6, e50 (2009).
81. Peng, G. S. & Yin, S. J. Effect of the allelic variants of aldehyde dehydrogenase ALDH22 and alcohol dehydrogenase ADH1B2 on blood acetaldehyde concentrations. Hum. Genomics 3, 121-127 (2009).
82. Marmot, M. G. et al. Alcohol and blood pressure: The INTERSALT study. BMJ 308, 1263-1267 (1994).
83. Chen, L., Davey Smith, G., Harbord, R. M. & Lewis, S. J. Alcohol intake and blood pressure: A systematic review implementing a Mendelian randomization approach. PLoS Med. 5, e52 (2008).
84. Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N. & Davey Smith, G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat. Med. 27, 1133-1163 (2008).
85. Davey Smith, G. Use of genetic markers and gene-diet interactions for interrogating population-level causal influences of diet on health. Genes Nutr. 6, 27-43 (2011).
86. Tabara, Y. et al. Mendelian randomization analysis in three Japanese populations supports a causal role of alcohol consumption in lowering low-density lipid cholesterol levels and particle numbers. Atherosclerosis 254, 242-248 (2016).
87. Lewis, S. J. & Davey Smith, G. Alcohol, ALDH2, and esophageal cancer: A meta-analysis which illustrates the potentials and limitations of a Mendelian randomization approach. Cancer Epidemiol. Biomarkers Prev. 14, 1967-1971 (2005).
88. Zuccolo, L. & Holmes, M. V. Commentary: Mendelian randomization-inspired causal inference in the absence of genetic data. Int. J. Epidemiol. http://dx.doi.org/10.1093/ije/dyw327 (2016).
89. Mokry, L. E. et al. Vitamin D and risk of multiple sclerosis: A Mendelian randomization study. PLoS Med. 12, e1001866 (2015).
90. Cabre, P. Migration and multiple sclerosis: The French West Indies experience. J. Neurol. Sci. 262, 117-121 (2007).
91. Dean, G. & Elian, M. Age at immigration to England of Asian and Caribbean immigrants and the risk of developing multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 63, 565-568 (1997).
92. Elian, M., Nightingale, S. & Dean, G. Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa and the West Indies. J. Neurol. Neurosurg. Psychiatry 53, 906-911 (1990).
93. Dean, G. & Kurtzke, J. F. On the risk of multiple sclerosis according to age at immigration to South Africa. Br. Med. J. 3, 725-729 (1971).
94. Navab, M. et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vasc. Biol. 16, 831-842 (1996).
95. Myung, S. K. et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ 346, f10 (2013).
96. Vivekananthan, D. P., Penn, M. S., Sapp, S. K., Hsu, A. & Topol, E. J. Use of antioxidant vitamins for the prevention of cardiovascular disease: metaanalysis of randomised trials. Lancet 361, 2017-2023 (2003).
97. Powers, K. M., Oberley, L. W. & Domann, F. E. in Oxidants in Biology: A Question of Balance (eds Valacchi, G. & Davis, P. A.) 183-201 (Springer, 2008).
98. Jung, O. et al. Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: in vivo and ex vivo evidence from ecSOD-deficient mice. Circ. Res. 93, 622-629 (2003).
99. Gongora, M. C. et al. Role of extracellular superoxide dismutase in hypertension. Hypertension 48, 473-481 (2006).
100. Juul, K. et al. Genetically reduced antioxidative protection and increased ischemic heart disease risk: The Copenhagen City Heart Study. Circulation 109, 59-65 (2004).
101. Siedlinski, M., van Diemen, C. C., Postma, D. S., Vonk, J. M. & Boezen, H. M. Superoxide dismutases, lung function and bronchial responsiveness in a general population. Eur. Respir. J. 33, 986-992 (2009).
102. Young, R. P. et al. Functional variants of antioxidant genes in smokers with COPD and in those with normal lung function. Thorax 61, 394-399 (2006).
103. Juul, K., Tybjaerg-Hansen, A., Marklund, S., Lange, P. & Nordestgaard, B. G. Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 173, 858-864 (2006).
104. Kobylecki, C. J., Afzal, S. & Nordestgaard, B. G. Does SOD3 R213G homozygosity influence morbidity, mortality, and lung function in the general population Antioxid. Redox Signal. 24, 884-891 (2016).
105. Hartney, J. M. et al. A common polymorphism in extracellular superoxide dismutase affects cardiopulmonary disease risk by altering protein distribution. Circ. Cardiovasc. Genet. 7, 659-666 (2014).
106. Kobylecki, C. J., Afzal, S., Davey Smith, G. & Nordestgaard, B. G. Genetically high plasma vitamin C, intake of fruit and vegetables, and risk of ischemic heart disease and all-cause mortality: A Mendelian randomization study. Am. J. Clin. Nutr. 101, 1135-1143 (2015).
107. Cook, N. R. et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch. Intern. Med. 167, 1610-1618 (2007).
108. Cholesterol Treatment Trialists' Collaborators et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380, 581-590 (2012).
109. Davey Smith, G. & Ebrahim, S. Mendelian randomization: prospects, potentials, and limitations. Int. J. Epidemiol. 33, 30-42 (2004).
110. McGill, H. C. Jr et al. Origin of atherosclerosis in childhood and adolescence. Am. J. Clin. Nutr. 72, 1307S-1315S (2000).
111. Strong, J. P., Malcom, G. T., Newman, W. P. III & Oalmann, M. C. Early lesions of atherosclerosis in childhood and youth: natural history and risk factors. J. Am. Coll. Nutr. 11 (Suppl.), 51S-54S (1992).
112. Rosengren, A. et al. Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey. Eur. Heart J. 27, 789-795 (2006).
113. Burgess, S. & Thompson, S. G. Multivariable Mendelian randomization: The use of pleiotropic genetic variants to estimate causal effects. Am. J. Epidemiol. 181, 251-260 (2015).
114. Aschard, H., Vilhjalmsson, B. J., Joshi, A. D., Price, A. L. & Kraft, P. Adjusting for heritable covariates can bias effect estimates in genome-wide association studies. Am. J. Hum. Genet. 96, 329-339 (2015).
115. Richiardi, L., Bellocco, R. & Zugna, D. Mediation analysis in epidemiology: methods, interpretation and bias. Int. J. Epidemiol. 42, 1511-1519 (2013).
116. Helgadottir, A. et al. Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nat. Genet. 48, 634-639 (2016).
117. Friedewald, W. T., Levy, R. I. & Fredrickson, D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499-502 (1972).
118. Niemi, J. et al. Estimation of VLDL, IDL, LDL, HDL2, apoAI, and apoB from the Friedewald inputs-apoB and IDL, but not LDL, are associated with mortality in type 1 diabetes. Ann. Med. 41, 451-461 (2009).
119. Shah, T. et al. Gene-centric analysis identifies variants associated with interleukin6 levels and shared pathways with other inflammation markers. Circ. Cardiovasc. Genet. 6, 163-170 (2013).
120. Fall, T. et al. The role of adiposity in cardiometabolic traits: A Mendelian randomization analysis. PLoS Med. 10, e1001474 (2013).
121. Burgess, S., Dudbridge, F. & Thompson, S. G. Re: "Multivariable Mendelian randomization: The use of pleiotropic genetic variants to estimate causal effects". Am. J. Epidemiol. 181, 290-291 (2015).
122. Hartwig, F. P., Davey Smith, G. & Bowden, J. Robust inference in two-sample Mendelian randomisation via the zero modal pleiotropy assumption. Int. J. Epidemiol. (in press).
123. Bowden, J. et al. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat. Med. 36, 1783-1802 (2017).
124. Ala-Korpela, M. & Davey Smith, G. Metabolic profilingmultitude of technologies with great research potential, but (when) will translation emerge Int. J. Epidemiol. 45, 1311-1318 (2016).
125. Mundra, P. A., Shaw, J. E. & Meikle, P. J. Lipidomic analyses in epidemiology. Int. J. Epidemiol. 45, 1329-1338 (2016).
126. Ganz, P. et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA 315, 2532-2541 (2016).
127. Hartwig, F. P., Davies, N. M., Hemani, G. & Davey Smith, G. Two-sample Mendelian randomisation: Avoiding the downsides of a powerful, widely applicable but potentially fallible technique. Int. J. Epidemiol. 6, 1717-1726 (2016).
128. Khera, A. V. & Kathiresan, S. Genetics of coronary artery disease: discovery, biology and clinical translation. Nat. Rev. Genet. http://dx.doi.org/ 10.1038/nrg.2016.160 (2017).
129. Hemani, G. et al. MRBase: A platform for systematic causal inference across the phenome using billions of genetic associations. Preprint at bioRxiv http://dx.doi.org/10.1101/078972 (2016).
130. Zheng, J. et al. LD Hub: A centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. Bioinformatics 33, 272-279 (2017).
131. Staley, J. R. et al. PhenoScanner: A database of human genotype-phenotype associations. Bioinformatics 32, 3207-3209 (2016).
132. Davey Smith, G., Paternoster, L. & Relton, C. When will Mendelian randomization become relevant for clinical practice and public health JAMA 317, 589-591 (2017).
133. Gibson, G. Rare and common variants: Twenty arguments. Nat. Rev. Genet. 13, 135-145 (2012).
134. Bush, W. S. & Moore, J. H. Chapter 11: genome-wide association studies. PLoS Comput. Biol. 8, e1002822 (2012).
135. Global Lipids Genetics Consortium et al. Discovery and refinement of loci associated with lipid levels. Nat. Genet. 45, 1274-1283 (2013).
136. Merino, J. et al. Genetically driven hyperglycemia increases risk of coronary artery disease separately from type 2 diabetes. Diabetes Care 40, 687-693 (2017).
137. Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629-634 (1997).
138. Bowden, J. et al. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MREgger regression: The role of the I2 statistic. Int. J. Epidemiol. 45, 1961-1974 (2016).
139. Wurtz, P. et al. Metabolic signatures of adiposity in young adults: Mendelian randomization analysis and effects of weight change. PLoS Med. 11, e1001765 (2014).
140. Emerging Risk Factors Collaboration et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993-2000 (2009).
141. Do, R. et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat. Genet. 45, 1345-1352 (2013).
142. Casas, J. P. et al. PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation 121, 2284-2293 (2010).
143. Cannon, C. P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372, 2387-2397 (2015).
144. Myocardial Infarction Genetics Consortium Investigators et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N. Engl. J. Med. 371, 2072-2082 (2014).
145. Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713-1722 (2017).
146. Cohen, J. C., Boerwinkle, E., Mosley, T. H. Jr & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264-1272 (2006).
147. Clarke, R. et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361, 2518-2528 (2009).
148. Dewey, F. E. et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N. Engl. J. Med. 374, 1123-1133 (2016).
149. Ridker, P. M., Pradhan, A., MacFadyen, J. G., Libby, P. & Glynn, R. J. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial. Lancet 380, 565-571 (2012).
150. Sattar, N. et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 375, 735-742 (2010).
151. Piepoli, M. F. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 37, 2315-2381 (2016).
152. Yun, K. E. et al. Alcohol and coronary artery calcification: An investigation using alcohol flushing as an instrumental variable. Int. J. Epidemiol. http://dx.doi.org/10.1093/ije/dyw237 (2017).